{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T08:04:05Z","timestamp":1694073845439},"reference-count":13,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,9,15]]},"DOI":"10.2169\/internalmedicine.2604-18","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T22:03:43Z","timestamp":1559858623000},"page":"2657-2662","source":"Crossref","is-referenced-by-count":3,"title":["Role of NS5A-L31\/Y93 Double Wild-type in Failure of Glecaprevir\/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis"],"prefix":"10.2169","volume":"58","author":[{"given":"Tomoya","family":"Sano","sequence":"first","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Akuta","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Kasuya","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichiro","family":"Fujiyama","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Sezaki","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Hosaka","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Saitoh","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Liver Research Laboratory, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuji","family":"Arase","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother 61: e02558, 2017.","DOI":"10.1128\/AAC.02558-16"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ng T, Tripathi R, Dekyhyar T, et al. <i>In vitro<\/i> antiviral activity and resistance profile of the next-generation hepatitis C virus NS3-4A protease inhibitor glecaprevir. Antimicrob Agents Chemother 62: e01620, 2017.","DOI":"10.1128\/AAC.01620-17"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kato N, Hijikata M, Ootsuyama Y, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 87: 9524-9528.","DOI":"10.1073\/pnas.87.24.9524"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. McPhee F, Hernandez D, Zhou N, et al. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir Ther 19: 479-490, 2014.","DOI":"10.3851\/IMP2729"},{"key":"5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","volume":"151","author":"JM Pawlotsky","year":"2016","unstructured":"5. Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151: 70-86, 2016.","journal-title":"Gastroenterology","ISSN":"http:\/\/id.crossref.org\/issn\/0016-5085","issn-type":"print"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64: 486-504, 2016.","DOI":"10.1016\/j.jhep.2015.09.011"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. K\u00f6ser CU, Fraser LJ, Ioannou A, et al. Rapid single-colony whole-genome sequencing of bacterial pathogens. J Antimicrob Chemother 69: 1275-1281, 2014.","DOI":"10.1093\/jac\/dkt494"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Krishnan P, Schnell G, Tripathi R, et al. Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan. Antimicrob Agents Chemother 62: e02217, 2017.","DOI":"10.1128\/AAC.02217-17"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Iio E, Ogawa S, Shimada N, et al. Serial changes of NS5A P32 deletion mutant in HCV genotype 1b patients after daclatasvir\/asunaprevir failure. Kanzo 59: 230-233, 2018 (in Japanese, Abstract in English).","DOI":"10.2957\/kanzo.59.230"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Akuta N, Sezaki H, Suzuki F, et al. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. J Med Virol 89: 1248-1254, 2017.","DOI":"10.1002\/jmv.24767"},{"key":"11","unstructured":"11. Dietz J, Susser S, Vermehren J, et al.; European HCV Resistance Study Group. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology 154: 976-988.e4, 2018."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Gane EJ, Shiffman ML, Etzkorn K, et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology 66: 1083-1089, 2017.","DOI":"10.1002\/hep.29256"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Izumi N, Takehara T, Chayama K, et al. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int 12: 356-367, 2018.","DOI":"10.1007\/s12072-018-9878-6"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/18\/58_2604-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T03:38:37Z","timestamp":1569037117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/18\/58_2604-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,15]]},"references-count":13,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2604-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,15]]}}}